摘要
目的:探讨卡托普利、安体舒通联合治疗慢性肺源性心脏病的疗效。方法:104例慢性肺源性心脏病患者,随机分为对照组及治疗组,每组52例,两组患者均实施常规治疗措施,治疗组在此基础上给予卡托普利联合安体舒通治疗20天,比较分析两组患者临床疗效及不良反应发生情况。结果:治疗组总有效率为90.4%,显著高于对照组的57.7%(P<0.05);两组患者均未出现严重不良反应,所有患者均成功完成所有疗程。结论:卡托普利、安体舒通联合治疗慢性肺源性心脏病治疗效果显著。
Objective：To investigate the treatment of chronic pulmonary heart disease after using captopril and spironolactone. Methods：A total of 104 patients with chronic pulmonary heart disease was studied,Which were divided into control group（52 cases） and treatment groups （52 cases）atrandom.Two groups were given the conventional treatment;the treatment group was given captopril and spironolactone based on the conventional treatment.Both of the groups were observed after 20 days of treatment.Results：The rate of the total efficiency in the treatment group was 90.4%compared with the control group 57.7%.The efficacy of the two groups was significant different（P〈0.05）.In the course of treatment,the two groups have no severe reaction.Conclusions：Captopril and spironolactone are effective in the efficacy of treatment of chronic pulmonary heart disease significantly.
出处
《中国医药导刊》
2014年第3期484-485,共2页
Chinese Journal of Medicinal Guide
